Compare ASTRAZENECA PHARMA with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs SUN PHARMA - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA SUN PHARMA ASTRAZENECA PHARMA/
SUN PHARMA
 
P/E (TTM) x 81.8 27.0 302.8% View Chart
P/BV x 23.0 2.3 987.6% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 ASTRAZENECA PHARMA   SUN PHARMA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
SUN PHARMA
Mar-19
ASTRAZENECA PHARMA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,278679 188.3%   
Low Rs883375 235.1%   
Sales per share (Unadj.) Rs228.4121.1 188.5%  
Earnings per share (Unadj.) Rs10.413.4 77.5%  
Cash flow per share (Unadj.) Rs16.320.7 78.6%  
Dividends per share (Unadj.) Rs02.75 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs98.8172.6 57.2%  
Shares outstanding (eoy) m25.002,399.26 1.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.74.4 108.7%   
Avg P/E ratio x104.239.4 264.5%  
P/CF ratio (eoy) x66.425.5 260.7%  
Price / Book Value ratio x10.93.1 358.1%  
Dividend payout %020.6 0.0%   
Avg Mkt Cap Rs m27,0081,264,650 2.1%   
No. of employees `0001.417.5 7.7%   
Total wages/salary Rs m1,53559,671 2.6%   
Avg. sales/employee Rs Th4,210.916,608.1 25.4%   
Avg. wages/employee Rs Th1,132.23,409.6 33.2%   
Avg. net profit/employee Rs Th191.11,833.8 10.4%   
INCOME DATA
Net Sales Rs m5,710290,659 2.0%  
Other income Rs m12310,255 1.2%   
Total revenues Rs m5,833300,914 1.9%   
Gross profit Rs m46363,076 0.7%  
Depreciation Rs m14717,533 0.8%   
Interest Rs m05,553 0.0%   
Profit before tax Rs m43850,246 0.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-12,144 0.0%   
Tax Rs m1796,009 3.0%   
Profit after tax Rs m25932,093 0.8%  
Gross profit margin %8.121.7 37.4%  
Effective tax rate %40.812.0 341.5%   
Net profit margin %4.511.0 41.1%  
BALANCE SHEET DATA
Current assets Rs m3,209310,692 1.0%   
Current liabilities Rs m2,070173,396 1.2%   
Net working cap to sales %20.047.2 42.3%  
Current ratio x1.61.8 86.5%  
Inventory Days Days7299 73.0%  
Debtors Days Days35112 31.3%  
Net fixed assets Rs m790232,477 0.3%   
Share capital Rs m502,399 2.1%   
"Free" reserves Rs m2,419411,691 0.6%   
Net worth Rs m2,469414,091 0.6%   
Long term debt Rs m015,226 0.0%   
Total assets Rs m4,605646,938 0.7%  
Interest coverage xNM10.0-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.20.4 276.0%   
Return on assets %5.65.8 96.7%  
Return on equity %10.57.8 135.4%  
Return on capital %17.710.2 174.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m30066,025 0.5%   
Fx outflow Rs m2,01538,610 5.2%   
Net fx Rs m-1,71527,415 -6.3%   
CASH FLOW
From Operations Rs m8821,965 0.4%  
From Investments Rs m-94-6,813 1.4%  
From Financial Activity Rs mNA-27,305 0.0%  
Net Cashflow Rs m-6-8,442 0.1%  

Share Holding

Indian Promoters % 0.0 63.7 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 5.1 5.8%  
FIIs % 15.7 23.0 68.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 8.3 109.6%  
Shareholders   12,856 133,026 9.7%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   PROCTER & GAMBLE HEALTH  CIPLA  TORRENT PHARMA  ALEMBIC LTD  WYETH LTD  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Oct 18, 2019 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS